- Fourth Carcinogen DMF Found in Blood-Pressure Pill Valsartan - Bloomberg
- Chinese Heart Drug Valsartan Recall Shows FDA Inspection Limits - Bloomberg
- J&J knew for decades that asbestos lurked in its Baby Powder
- Pennsylvania Xarelto Bleeding Lawsuit Trials Begin Next Month
- Editorial: Fighting back against Big Pain, without much help from Congress | Editorial | stltoday.com
- Pennsylvania’s First Xarelto Lawsuit Trial Concludes With $28 Million Verdict for Plaintiff, Bernstein Liebhard LLP Reports | Life Pulse Health
- California Woman Files Celect® IVC Filter Lawsuit – Daily Hornet | Breaking News That Stings!
- Wright Medical Pays $90 Million to Settle Remaining Hip Lawsuits
- Filings Fly as Xarelto Mass Tort Prepares for Trial | Law.com
- Father blames NuvaRing manufacturers for daughter's death | St. Louis Record
$5.5 Million Ruling in First Transvaginal Mesh Case
A treatment for pelvic organ prolapse and stress urinary incontinence, the transvaginal mesh has been linked to many serious complications. This device is a piece of mesh, surgically implanted through the vagina. This hammock-like device supports organs such as the bladder, rectum, and uterus to keep them from dropping when a woman's pelvic muscles are too weakened to support them. With hundreds of state and federal lawsuits underway for the manufacturers of this device, a California jury has finally reached a verdict on the first of these suits.
The jury ruled in the favor of Christine Scott, who will endure a lifetime of chronic pain after attempts to remove two transvaginal mesh devices were unsuccessful. Scott sued C.R. Bard and a doctor, claiming the device is responsible for her injuries. Scott has undergone eight separate procedures, along with nine revision surgeries, all which proved unsuccessful at removing the devices. Scott was awarded $5 million in her suit. The damage to Scott's body has left her no longer able to have sexual intercourse. Due to this fact, her husband was awarded $500,000 in the suit as well.
The transvaginal mesh was tested on rats, rabbits and sheep before prior to being used on women. However, Bard continued to market its Avulta line of transvaginal mesh devices even after several legal complaints of complications emerged. It wasn't until July that Bard put a stop to the use of these devices in the United States, following a request from the FDA to run further testing. The FDA has stated that the side effects of this device are not rare and it is no longer believed to be safer than the surgical treatment option.
The jury ruled that C.R. Bard was 60 percent responsible for Scott's complications. Bard's attorneys have expressed intentions to appeal this ruling, stating, "Throughout the case, we clearly have empathized with Mrs. Scott's injuries. We just don't feel that they were the result of the Avaulta Plus product or the conduct of our company???"
With hundreds of other cases in the works, this landmark ruling has set the precedent for future proceedings. The ongoing lawsuits have been divided into five multidistrict litigations. C.R. Bard is the defendant in one of these litigations
Recent Posts
By Date
- June 2019
- February 2019
- January 2019
- March 2018
- February 2018
- January 2018
- November 2017
- October 2017
- September 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- December 2015
- November 2015
- August 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014